GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT06790160

Recruiting

Study of Patients Being Treated With Anti-obesity Medication

Observational Study of Patients Being Treated With Anti-obesity Medication

Lead sponsor

Texas Tech University

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Enrollment

100

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoints

•Lean mass•Total fat mass•Handgrip Strength

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06790160

Org study ID2024-1109

Timeline

Milestones

Study first posted2025-01-23actual

Study start2025-01-31actual

Last update posted2026-05-15actual

Primary completion2027-12estimated (month precision)

Study completion2027-12estimated (month precision)

Assets

Investigational agents

Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

The study population is eligible individuals who are undergoing standard obesity medication treatment at a specified virtual obesity medicine practice.

Inclusion criteria

•Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity.

•Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.

Exclusion criteria

•Patients with type 2 diabetes.

•Patients who report not being willing or able to complete the assessments included in this research study.

•Patients who are currently pregnant or trying to become pregnant.

Endpoints (23)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Other (unclassified)

Other clinical outcomes

Glycemic / diabetes

Weight & body composition

7 endpoints

Primary/protocol endpoint

Change in Total Lean Soft Tissue

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

Lean mass

change from baseline, improvement

Primary/protocol endpoint

Change in Appendicular Lean Soft Tissue

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

Lean mass

change from baseline, improvement

Primary/protocol endpoint

Change in Total Fat Mass

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Change in Total Body Mass

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

change from baseline, improvement

Secondary/protocol endpoint

Change in Total Body Fat Percentage

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Change in Total Bone Mineral Content

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

change from baseline, descriptive

Secondary/protocol endpoint

Change in Visceral Fat

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

Visceral fat, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Other/protocol endpoint

Change in Hemoglobin A1C

Time frame:From baseline assessment to last available time point.

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

Change in Glucose

Time frame:From baseline assessment to last available time point.

change from baseline, improvement

Cardiometabolic biomarkers

5 endpoints

Other/protocol endpoint

Change in Total Cholesterol

Time frame:From baseline assessment to last available time point.

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Other/protocol endpoint

Change in LDL Cholesterol

Time frame:From baseline assessment to last available time point.

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Other/protocol endpoint

Change in HDL Cholesterol

Time frame:From baseline assessment to last available time point.

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Other/protocol endpoint

Change in Triglycerides

Time frame:From baseline assessment to last available time point.

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Other/protocol endpoint

Change in Blood Pressure

Time frame:From baseline assessment to last available time point.

change from baseline, improvement

Other clinical outcomes

4 endpoints

Primary/protocol endpoint

Change in Handgrip Strength

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

change from baseline, improvement

Other/protocol endpoint/low confidence

Sugar Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

change from baseline, improvement

Other/protocol endpoint/low confidence

Muscle-strengthening activity level

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Other/protocol endpoint

Physical activity level

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Other (unclassified)

5 endpoints

Other/protocol endpoint/low confidence

Energy Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

change from baseline, descriptive

Other/protocol endpoint/low confidence

Protein Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Other/protocol endpoint

Carbohydrate Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Other/protocol endpoint/low confidence

Fat Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Other/protocol endpoint/low confidence

Fiber Intake

Time frame:From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.